Overview

Ridaforolimus in Patients With Hepatic Insufficiency (MK-8669-046)

Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the pharmacokinetics of ridaforolimus including the area under the concentration-time curve (AUC[0-infinity]) and maximum concentration (Cmax) after administration of a single dose of ridaforolimus in patients with moderate hepatic insufficiency and healthy matched control subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Collaborator:
Ariad Pharmaceuticals
Treatments:
Sirolimus